HomeCompareEIGR vs GBDC

EIGR vs GBDC: Dividend Comparison 2026

EIGR yields 115.94% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $13.53M in total portfolio value· pulled ahead in Year 10
10 years
EIGR
EIGR
● Live price
115.94%
Share price
$1.73
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.32M
Annual income
$2,715,715.87
Full EIGR calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — EIGR vs GBDC

📍 GBDC pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIGRGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIGR + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIGR pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIGR
Annual income on $10K today (after 15% tax)
$9,855.07/yr
After 10yr DRIP, annual income (after tax)
$2,308,358.49/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $11,674,765.27/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIGR + GBDC for your $10,000?

EIGR: 50%GBDC: 50%
100% GBDC50/50100% EIGR
Portfolio after 10yr
$14.09M
Annual income
$9,583,224.86/yr
Blended yield
68.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EIGR right now

EIGR
Analyst Ratings
11
Buy
Consensus: Buy
Altman Z
-24.5
Piotroski
4/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIGR buys
0
GBDC buys
0
No recent congressional trades found for EIGR or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIGRGBDC
Forward yield115.94%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$7.32M$20.85M
Annual income after 10y$2,715,715.87$16,450,733.83
Total dividends collected$6.64M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: EIGR vs GBDC ($10,000, DRIP)

YearEIGR PortfolioEIGR Income/yrGBDC PortfolioGBDC Income/yrGap
1$22,294$11,594.20$12,492$1,791.70+$9.8KEIGR
2$48,012$24,157.34$16,527$3,160.58+$31.5KEIGR
3$99,994$48,621.05$23,588$5,904.90+$76.4KEIGR
4$201,631$94,637.59$37,141$11,901.65+$164.5KEIGR
5$394,091$178,346.07$66,205$26,463.38+$327.9KEIGR
6$747,454$325,775.96$137,452$66,612.65+$610.0KEIGR
7$1,377,237$577,460.92$342,372$195,298.53+$1.03MEIGR
8$2,468,047$994,404.26$1,053,292$686,954.33+$1.41MEIGR
9$4,306,232$1,665,421.46$4,111,439$2,984,416.95+$194.8KEIGR
10← crossover$7,323,384$2,715,715.87$20,849,974$16,450,733.83$13.53MGBDC

EIGR vs GBDC: Complete Analysis 2026

EIGRStock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Full EIGR Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this EIGR vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIGR vs SCHDEIGR vs JEPIEIGR vs OEIGR vs KOEIGR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.